Merck KGaA suffers setback on cancer drug
German pharmaceuticals maker Merck KGaA said Thursday that phase III clinical trials of its gastric cancer drug Erbitux had shown no benefits for patients.
View full post on Health News Headlines – Yahoo! News
Leave a Reply